Role of Portal Vein Tumor Thrombosis in Quantitative Perfusion Analysis of Contrast-Enhanced Ultrasound of Hepatocellular Carcinoma

Wang, Zhu; Liu, Guangjian; Lü, Ming-De; Xie, Xian-Jin; Wang, Wei; Xu, Zuo-Feng; Lin, Manxia; Chen, Li‐da

doi:10.1016/j.ultrasmedbio.2014.12.012

Cited by 7 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the reflection of perfusion features, DCE-US has been reported to correlate with histopathological characteristics of HCC, including grade of differentiation [27], portal vein thrombosis [28], unpaired arteries [29], MVD [30], and VEGF expression [31]. Choi and colleagues established three rat hepatoma models and showed that MVD was positively correlated with IMAX and negatively correlated with mTT and TTP [32].…”

Section: Discussionmentioning

confidence: 99%

Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation

Yang

Zhou

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: Previous studies have reported that parameters of dynamic contrast-enhanced ultrasound (DCE-US) could predict prognosis of hepatocellular carcinoma (HCC) patients after antiangiogenic therapies. In this study, we aimed to investigate the correlation of DCE-US parameters and the prognosis of HCC patients after microwave ablation (MWA). Materials and methods: Between June 2012 and January 2018, a total of 35 HCC patients who received MWA with a curative intent were enrolled. Pre-ablation DCE-US, liver biopsy, CD34 staining, and vascular endothelial growth factor (VEGF) staining were performed. DCE-US parameters were extracted from time-intensity curves using SonoLiver software. The correlation of DCE-US parameters with histopathology results and overall survival (OS) were investigated. Results: Quantitative analysis showed that IMAX, RT, TTP, and mTT of HCC were statistically different with that of reference liver parenchyma (all p ＜ .001). Microvessel density was shown to be positively correlated with IMAX and negatively correlated with TTP (r ¼ 0.755 and À0.647, both p ＜ .01). Additionally, positive correlations were observed between IMAX and VEGF expression (r ¼ 0.665, p ＜ .01). After a median follow-up of 22 months (range 6-64 months), local recurrence was detected in three patients. Largest diameter and TTP were shown to help predict OS in univariate and multivariate analyses. Conclusion: DCE-US parameter may help predict the outcome of HCC patients after MWA, though further study is still needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation

Yang

Zhou

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…A trend toward correlation between the increase in time to PI (TP) and tumor response was also observed, although this association was not statistically significant [48]. Moreover, in another study TP at 1 month was the best discriminator for responders and non-responders (273 days versus 214 days) and this parameter continued to increase in the responder group because of the impact of antiangiogenetic treatments on dynamic flow [49]. However, it is worth mentioning that the presence of portal vein thrombosis influences hemodynamic parameters and TP results.…”

Section: Systemic Therapies and Ceusmentioning

confidence: 93%

Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma

Faccia

Garcovich

Ainora

et al. 2022

Cancers

View full text Add to dashboard Cite

The capacity of contrast-enhanced ultrasound (CEUS) to detect microvessel perfusion has received much attention in cancer imaging since it can be used to evaluate the enhancement patterns of the lesions during all vascular phases in real time, with higher temporal resolution as compared other imaging modalities. A rich body of literature has demonstrated the potential usefulness of CEUS in the assessment of HCC in response to both locoregional and systemic therapies. It is useful to evaluate the efficacy of ablation immediately after treatment to provide guidance for the retreatment of residual unablated tumors. In patients treated with transarterial chemoembolization (TACE), CEUS showed a high degree of concordance with computed tomography and magnetic resonance for the differentiation of responders from non-responders. Dynamic CEUS (D-CEUS) has emerged as a promising tool for the depicting changes in tumor perfusion during anti-angiogenetic treatment that can be associated with tumor response and clinical outcome. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure in different stages of the disease.

show abstract

“…It is the time from the rising of the intensity up to a decrease to 50% of IMAX. The QOF is used to test the QOF between raw data and the fitted mathematical model . These tumor parameters were compared between ROI tumor and ROI max .…”

Section: Methodsmentioning

confidence: 99%

“…The QOF is used to test the QOF between raw data and the fitted mathematical model. 21 These tumor parameters were compared between ROI tumor and ROI max . The differences between parameters of the ROI max and those of ROI refer (ΔPar = Par max -Par refer ) were calculated.…”

Section: Tumor Perfusion Evaluation Using Ceus By Mrecistmentioning

confidence: 99%

Ultrasomics for Early Evaluation of the Tumor Response to MicroRNA‐122 in a Nude Mouse Hepatocellular Carcinoma Model

Guo¹,

Chen²,

Li³

et al. 2019

J of Ultrasound Medicine

Self Cite

View full text Add to dashboard Cite

Objectives-To explore the value of ultrasomics in temporal monitoring of tumor changes in response to gene therapy in hepatocellular carcinoma compared with methods according to the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST).Methods-Hepatocellular carcinoma-bearing mice were injected intratumorally with microRNA-122 (miR-122) mimics and an miR-122 negative control in the treatment and control groups, respectively. The injections were performed every 3 days for 5 times (on days 0, 3, 6, 9, and 12). Before each injection and at the experiment ending, 2-dimensional ultrasound imaging was performed for tumor size measurement with RECIST and computing a quantitative imaging analysis with ultrasomics. To analyze the tumor perfusion by mRECIST, perfusion parameters were analyzed offline based on dynamic contrast-enhanced ultrasound image videos using SonoLiver software (TomTec, Unterschleissheim, Germany) on day 13. Tumor miR-122 expression was then analyzed by real-time reverse transcription-polymerase chain reaction experiments.Results-Tumors in mice treated with miR-122 mimics demonstrated a mean AE SD 763-AE 60-fold increase in miR-122 levels compared with tumors in the control group. With RECIST, a significant therapeutic response evaluated by tumor size changes was detected after day 9 (days 9, 12, and 13; P < .001). With mRECIST, no parameters showed significant differences (P > .05). Significant different features of the 2dimensional ultrasound images between the groups were detected by the ultrasomics analysis, and the model could be successfully built. The ultrasomics score values between the groups were statistically significant after day 6 (days 6, 9, 12, and 13; P < .05).Conclusions-Ultrasomics revealed significant changes after the second injection of miR-122, showing the potential as an important imaging biomarker for gene therapy.

show abstract

Role of Portal Vein Tumor Thrombosis in Quantitative Perfusion Analysis of Contrast-Enhanced Ultrasound of Hepatocellular Carcinoma

Cited by 7 publications

References 23 publications

Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation

Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation

Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma

Ultrasomics for Early Evaluation of the Tumor Response to MicroRNA‐122 in a Nude Mouse Hepatocellular Carcinoma Model

Contact Info

Product

Resources

About